Wellington Management Group LLP decreased its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 32.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,985,976 shares of the company's stock after selling 2,353,028 shares during the period. Wellington Management Group LLP owned approximately 5.84% of Syndax Pharmaceuticals worth $95,980,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. State Street Corp increased its stake in Syndax Pharmaceuticals by 4.1% in the 3rd quarter. State Street Corp now owns 3,770,826 shares of the company's stock worth $72,588,000 after purchasing an additional 148,491 shares during the period. Sofinnova Investments Inc. grew its holdings in shares of Syndax Pharmaceuticals by 33.9% in the second quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company's stock worth $44,215,000 after purchasing an additional 545,129 shares during the last quarter. First Turn Management LLC increased its stake in shares of Syndax Pharmaceuticals by 85.4% in the third quarter. First Turn Management LLC now owns 1,187,165 shares of the company's stock worth $22,853,000 after buying an additional 546,776 shares during the period. Millennium Management LLC raised its holdings in Syndax Pharmaceuticals by 56.3% during the 2nd quarter. Millennium Management LLC now owns 1,065,508 shares of the company's stock valued at $21,875,000 after buying an additional 383,634 shares during the last quarter. Finally, Sphera Funds Management LTD. boosted its position in Syndax Pharmaceuticals by 25.9% during the 3rd quarter. Sphera Funds Management LTD. now owns 1,034,846 shares of the company's stock valued at $19,921,000 after buying an additional 212,799 shares during the period.
Analysts Set New Price Targets
SNDX has been the topic of a number of analyst reports. Citigroup boosted their price objective on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a "buy" rating in a research report on Tuesday, November 19th. UBS Group assumed coverage on Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a "buy" rating and a $37.00 price target for the company. Stifel Nicolaus increased their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Bank of America boosted their target price on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, August 15th. Finally, StockNews.com lowered Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, November 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, Syndax Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $37.64.
Read Our Latest Stock Analysis on SNDX
Syndax Pharmaceuticals Stock Performance
Shares of SNDX traded down $0.62 during mid-day trading on Tuesday, reaching $14.94. The company had a trading volume of 3,047,997 shares, compared to its average volume of 1,184,414. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -4.29 and a beta of 0.86. The firm has a 50-day moving average price of $18.22 and a 200 day moving average price of $19.62. Syndax Pharmaceuticals, Inc. has a 52 week low of $14.57 and a 52 week high of $25.34.
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same period last year, the firm posted ($0.73) earnings per share. As a group, research analysts forecast that Syndax Pharmaceuticals, Inc. will post -2.39 earnings per share for the current fiscal year.
Syndax Pharmaceuticals Profile
(
Free Report)
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Further Reading
![Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)](https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&Symbol=SNDX)
Before you consider Syndax Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.
While Syndax Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.